Skip to main content
Clinical Trials/NCT00414297
NCT00414297
Completed
Not Applicable

External Counterpulsation (ECP) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease

Insel Gruppe AG, University Hospital Bern1 site in 1 country30 target enrollmentAugust 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
30
Locations
1
Primary Endpoint
Collateral flow index (CFI)
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by percutaneous coronary intervention (PCI) is to evaluate the efficacy of External Counterpulsation (ECP) with regard to the promotion of coronary collateral growth.

Detailed Description

Alternative strategies for the promotion of coronary collaterals (arteriogenesis) are a promising therapeutic alternative for at least 20% of all Patients with Coronary Artery Disease (CAD). Beside growth factors, physical exercise has been shown to improve coronary collateral function. Extracorporal Counterpulsation (ECP) mimics physical exercise in a standardized way. Before and after ECP treatment, a quantitative invasive assessment of absolute collateral flow (by calculating the CFI, i.e. Collateral Flow Index) and myocardial perfusion is performed (with calculation of the CPI, i.e. Collateral Perfusion Index and MPR, i.e. Myocardial Perfusion Reserve). The study setting is single-blinded, sham-controlled and proceptive .

Registry
clinicaltrials.gov
Start Date
August 2006
End Date
June 2009
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years old
  • 1- to 3-vessel coronary artery disease (CAD)
  • Stable angina pectoris
  • At least 1 stenotic lesion suitable for PCI within the next 4 weeks
  • No Q-wave myocardial infarction in the area undergoing CFI measurement
  • Written informed consent to participate in the study

Exclusion Criteria

  • Patients admitted as emergencies
  • Acute myocardial infarction within the last 3 months
  • Unstable CAD
  • CAD treated best by CABG
  • Coronary stenotic lesion to be treated ad-hoc or within \< 4 weeks
  • Severe valve disease
  • Pulmonary artery hypertension
  • Congestive heart failure
  • Atrial fibrillation
  • Thrombophlebitis and/or deep vein thrombosis

Outcomes

Primary Outcomes

Collateral flow index (CFI)

Time Frame: 21 days

Coronary collateral resistance (Rcoll)

Time Frame: 21 days

Secondary Outcomes

  • Myocardial perfusion reserve(21 days)

Study Sites (1)

Loading locations...

Similar Trials